Regan J W, DeMarinis R M, Lefkowitz R J
Biochem Pharmacol. 1985 Oct 15;34(20):3667-72. doi: 10.1016/0006-2952(85)90228-x.
An arylazide photoaffinity probe for alpha 2-adrenoceptors has been developed and characterized. The compound, 3-methyl-6-chloro-9-azido-1H-2,3,4,5-tetrahydro-3-benzazepine (SKF 102229), had a Ki for the human platelet alpha 2-adrenoceptor of approximately 40 nM. Upon exposure to ultraviolet light, SKF 102229 irreversibly blocked the binding of [3H]yohimbine to both membrane bound and solubilized, partially purified, receptors. The extent of alpha 2-adrenoceptor blockade was dependent upon both the length of exposure to ultraviolet light and the concentration of SKF 102229. Typically, a 60% decrease in alpha 2-adrenoceptor number is obtained following 8 min of photolysis in the presence of 100 nM SKF 102229. The pharmacologic characteristics of the irreversible blockade produced by SKF 102229 were those of an alpha 2-adrenoceptor. Thus, photodependent, irreversible blockade of alpha 2-adrenoceptors by SKF 102229 was prevented by the concomitant presence of phentolamine or p-aminoclonidine but not by prazosin. Given its specificity and efficient blockade of the ligand binding site, SKF 102229 should prove useful for studies of the structure and function of alpha 2-adrenoceptors.
一种用于α2肾上腺素能受体的芳基叠氮光亲和探针已被开发并表征。该化合物3-甲基-6-氯-9-叠氮基-1H-2,3,4,5-四氢-3-苯并氮杂卓(SKF 102229)对人血小板α2肾上腺素能受体的Ki约为40 nM。暴露于紫外光下时,SKF 102229不可逆地阻断[3H]育亨宾与膜结合以及溶解的、部分纯化的受体的结合。α2肾上腺素能受体的阻断程度取决于紫外光照射时间和SKF 102229的浓度。通常,在100 nM SKF 102229存在下光解8分钟后,α2肾上腺素能受体数量减少60%。SKF 102229产生的不可逆阻断的药理学特征是α2肾上腺素能受体的特征。因此,酚妥拉明或对氨基可乐定的同时存在可防止SKF 102229对α2肾上腺素能受体的光依赖性不可逆阻断,而哌唑嗪则不能。鉴于其特异性和对配体结合位点的有效阻断,SKF 102229应被证明对α2肾上腺素能受体的结构和功能研究有用。